Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical
trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients
with type 2 diabetes. Subjects treated with oral antidiabetic drug(s) (OAD(s)) should
continue their current OAD treatment at the stable, prerandomisation dose level and dosing
frequency.